FR23C1030I1 - Composes heterocycliques substitues par amide, utiles comme modulateurs d'il-12, il-23 et/ou de ifn-alpha - Google Patents

Composes heterocycliques substitues par amide, utiles comme modulateurs d'il-12, il-23 et/ou de ifn-alpha

Info

Publication number
FR23C1030I1
FR23C1030I1 FR23C1030C FR23C1030C FR23C1030I1 FR 23C1030 I1 FR23C1030 I1 FR 23C1030I1 FR 23C1030 C FR23C1030 C FR 23C1030C FR 23C1030 C FR23C1030 C FR 23C1030C FR 23C1030 I1 FR23C1030 I1 FR 23C1030I1
Authority
FR
France
Prior art keywords
ifn
modulators
amide
alpha
substituted heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1030C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1030(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FR23C1030I1 publication Critical patent/FR23C1030I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR23C1030C 2012-11-08 2023-08-14 Composes heterocycliques substitues par amide, utiles comme modulateurs d'il-12, il-23 et/ou de ifn-alpha Active FR23C1030I1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723840P 2012-11-08 2012-11-08
PCT/US2013/068846 WO2014074661A1 (en) 2012-11-08 2013-11-07 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES

Publications (1)

Publication Number Publication Date
FR23C1030I1 true FR23C1030I1 (fr) 2023-10-13

Family

ID=49876960

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1030C Active FR23C1030I1 (fr) 2012-11-08 2023-08-14 Composes heterocycliques substitues par amide, utiles comme modulateurs d'il-12, il-23 et/ou de ifn-alpha

Country Status (39)

Country Link
US (6) USRE47929E1 (hr)
EP (3) EP2922846B1 (hr)
JP (3) JP6407159B2 (hr)
KR (1) KR102195194B1 (hr)
CN (1) CN104884454B (hr)
AR (1) AR094452A1 (hr)
AU (4) AU2013341186B2 (hr)
BR (1) BR112015010102B1 (hr)
CA (1) CA2890981C (hr)
CL (1) CL2015001231A1 (hr)
CY (2) CY1121188T1 (hr)
DK (2) DK3495358T3 (hr)
EA (1) EA028814B1 (hr)
ES (2) ES2914793T3 (hr)
FI (1) FIC20230028I1 (hr)
FR (1) FR23C1030I1 (hr)
HK (1) HK1215255A1 (hr)
HR (2) HRP20220766T1 (hr)
HU (3) HUE059409T2 (hr)
IL (1) IL238610A0 (hr)
LT (3) LT2922846T (hr)
MA (1) MA38072A1 (hr)
MX (2) MX2015005731A (hr)
MY (2) MY194668A (hr)
NL (1) NL301238I2 (hr)
NO (1) NO2023032I1 (hr)
NZ (1) NZ708859A (hr)
PE (1) PE20150944A1 (hr)
PH (1) PH12015501004A1 (hr)
PL (2) PL3495358T3 (hr)
PT (2) PT3495358T (hr)
RS (2) RS63328B1 (hr)
SG (3) SG10201706985UA (hr)
SI (2) SI2922846T1 (hr)
TR (1) TR201820824T4 (hr)
TW (1) TWI605041B (hr)
UY (1) UY35126A (hr)
WO (1) WO2014074661A1 (hr)
ZA (1) ZA201504052B (hr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63328B1 (sr) * 2012-11-08 2022-07-29 Bristol Myers Squibb Co Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn alfa odgovora
AU2013341195B2 (en) 2012-11-08 2017-09-21 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
JP6458038B2 (ja) 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
US9834548B2 (en) 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
PL3757097T3 (pl) * 2015-11-26 2022-07-25 Novartis Ag Pochodne diaminopirydyny
AU2017342464B2 (en) 2016-10-14 2021-09-16 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
TW201827423A (zh) 2016-12-13 2018-08-01 美商必治妥美雅史谷比公司 做為IL-12, IL-23及/或IFNα反應調節劑之經烷基醯胺取代之雜芳基化合物氧化膦
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
EP4338802A3 (en) 2017-03-08 2024-09-04 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
EP3601270A1 (en) * 2017-03-30 2020-02-05 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
AU2018371010C1 (en) 2017-11-21 2024-09-26 Bristol-Myers Squibb Company Sulfone pyridine alkyl amide-substituted heteroaryl compounds
WO2019178079A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
WO2019183186A1 (en) * 2018-03-22 2019-09-26 Bristol-Myers Squibb Company Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2019232138A1 (en) 2018-05-31 2019-12-05 Bristol-Myers Squibb Company Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
JP2022502515A (ja) 2018-10-15 2022-01-11 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
SG11202104017VA (en) * 2018-10-22 2021-05-28 Esker Therapeutics Inc Tyk2 inhibitors and uses thereof
CA3118094A1 (en) * 2018-10-30 2020-05-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
CN113271938A (zh) 2018-11-30 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
CA3126034A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN115448910B (zh) * 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
CN113365982A (zh) * 2019-01-30 2021-09-07 百时美施贵宝公司 酰胺二取代的吡啶或哒嗪化合物
WO2020222773A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
KR20220020890A (ko) * 2019-06-12 2022-02-21 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 염 형태
WO2021011513A1 (en) 2019-07-16 2021-01-21 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
JP2022542704A (ja) * 2019-08-01 2022-10-06 インテグラル バイオサイエンシーズ プライベート リミテッド キナーゼインヒビターとしての複素環式化合物およびその使用
BR112022004451A2 (pt) 2019-09-13 2022-06-21 Nimbus Saturn Inc Antagonistas de hpk1 e usos dos mesmos
CN114727949A (zh) 2019-09-18 2022-07-08 百时美施贵宝公司 Tyk2抑制剂的剂型
US20230039086A1 (en) * 2019-12-17 2023-02-09 Crystal Pharmaceutical (Suzhou) Co., Ltd. Bms-986165 crystal form, preparation method therefor and use thereof
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
US20230049130A1 (en) * 2020-01-19 2023-02-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. Deucravacitinib crystal form, preparation method therefor and use thereof
CN115003667A (zh) * 2020-02-26 2022-09-02 百济神州有限公司 Tyk-2抑制剂
PL4038063T3 (pl) * 2020-03-11 2024-07-15 Beijing Innocare Pharma Tech Co., Ltd. Związki heterocykliczne do hamowania aktywności tyk2
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
CN113563309A (zh) * 2020-04-28 2021-10-29 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
JP2023523438A (ja) * 2020-04-28 2023-06-05 ブリストル－マイヤーズ スクイブ カンパニー 置換ヘテロ環式化合物
CN113735837B (zh) * 2020-05-28 2023-09-01 江苏先声药业有限公司 哒嗪类化合物及其用途
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
JP2023534492A (ja) * 2020-07-24 2023-08-09 上▲海▼翰森生物医▲薬▼科技有限公司 ピリダジン誘導体遊離塩基の結晶形態、並びにその調製方法及びその使用
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
JP2023541997A (ja) 2020-09-18 2023-10-04 ブリストル－マイヤーズ スクイブ カンパニー 膨潤性コアを含むｔｙｋ２阻害薬の剤形
WO2022083649A1 (zh) * 2020-10-20 2022-04-28 杭州领业医药科技有限公司 哒嗪衍生物的晶型
WO2022100710A1 (en) * 2020-11-12 2022-05-19 Cullgen (Shanghai) , Inc. Tyrosine kinase 2 (tyk2) degradation compounds and methods of use
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN116547276A (zh) * 2020-12-08 2023-08-04 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
WO2022165141A1 (en) 2021-01-29 2022-08-04 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
EP4288430A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
BR112023016614A2 (pt) 2021-02-19 2023-11-07 Sudo Biosciences Ltd Inibidores de tyk2 e usos dos mesmos
EP4294807A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
CN117295737A (zh) 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
EP4308556A1 (en) * 2021-03-16 2024-01-24 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
KR20230163469A (ko) 2021-03-29 2023-11-30 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
EP4313989A1 (en) 2021-03-29 2024-02-07 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US20240182429A1 (en) * 2021-03-30 2024-06-06 Zhejiang Wenda Pharma Technology Ltd. Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use
CN115197196B (zh) * 2021-04-06 2024-06-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
AU2022268464A1 (en) 2021-05-04 2023-12-21 Shanghai Zheye Biotechnology Co. Ltd. Nitrogen-containing heterocyclic pyridine compound
JP2024518792A (ja) 2021-05-14 2024-05-02 ブリストル－マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
EP4337656A1 (en) * 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
AU2022271794A1 (en) * 2021-05-14 2024-01-04 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
EP4361138A1 (en) * 2021-06-22 2024-05-01 Medshine Discovery Inc. Sulfoximine compound and use thereof
WO2023284869A1 (zh) * 2021-07-15 2023-01-19 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
CN118119614A (zh) * 2021-08-20 2024-05-31 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
TW202313035A (zh) * 2021-08-21 2023-04-01 美商傳達治療有限公司 Ｊａｋ２抑制劑及其使用方法
IL311624A (en) 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
KR20240070634A (ko) 2021-09-30 2024-05-21 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제에 대한 반응성을 결정하는 방법
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
WO2023076515A1 (en) 2021-10-28 2023-05-04 Bristol-Myers Squibb Company Topical formulations of deucravacitinib
WO2023102085A1 (en) 2021-12-01 2023-06-08 Teva Czech Industries S.R.O. Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
EP4448514A1 (en) * 2021-12-16 2024-10-23 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
EP4206196A1 (en) 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
WO2023231997A1 (zh) * 2022-05-31 2023-12-07 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
TW202416950A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 雜芳基甲醯胺及相關gpr84拮抗劑及其用途
TW202416972A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 經取代之吡啶酮gpr84拮抗劑及其用途
WO2024102683A1 (en) * 2022-11-08 2024-05-16 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2024127363A1 (en) 2022-12-16 2024-06-20 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof
CN116284040B (zh) * 2023-01-05 2024-05-28 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其医药用途
WO2024165000A1 (zh) * 2023-02-07 2024-08-15 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
CN116162093B (zh) * 2023-04-25 2023-06-23 中南大学湘雅医院 一种tyk2抑制剂化合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
EP1184376B1 (en) * 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2356544C (en) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines and pyridopyridazines
CN1688340A (zh) 2002-07-15 2005-10-26 韦思公司 调节t辅助(th)细胞发育和功能的方法和组合物
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
MX2012010265A (es) 2010-03-17 2012-10-01 Hoffmann La Roche Compuestos de imidazopiridina, composiciones y metodos de uso.
WO2012035039A1 (en) 2010-09-15 2012-03-22 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
CN103313987A (zh) 2010-11-19 2013-09-18 弗·哈夫曼-拉罗切有限公司 吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
JP5878178B2 (ja) * 2011-09-30 2016-03-08 大鵬薬品工業株式会社 １，２，４−トリアジン−６−カルボキサミド誘導体
KR20140108594A (ko) * 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
WO2014060371A1 (en) * 2012-10-19 2014-04-24 F. Hoffmann-La Roche Ag Inhibitors of syk
AU2013341185B2 (en) 2012-11-08 2017-07-13 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses
RS63328B1 (sr) * 2012-11-08 2022-07-29 Bristol Myers Squibb Co Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn alfa odgovora
AU2013341195B2 (en) 2012-11-08 2017-09-21 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
EP3601270A1 (en) * 2017-03-30 2020-02-05 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Also Published As

Publication number Publication date
HRP20220766T1 (hr) 2022-09-16
US20150299183A1 (en) 2015-10-22
JP6407159B2 (ja) 2018-10-17
PH12015501004B1 (en) 2015-07-27
PT3495358T (pt) 2022-06-02
AU2013341186A1 (en) 2015-07-02
JP2016506369A (ja) 2016-03-03
MX2020003156A (es) 2020-07-29
EA028814B1 (ru) 2018-01-31
JP2018154636A (ja) 2018-10-04
PT2922846T (pt) 2018-12-19
AU2017201076A1 (en) 2017-03-09
LT3495358T (lt) 2022-05-25
EA201590917A1 (ru) 2015-09-30
RS63328B1 (sr) 2022-07-29
TWI605041B (zh) 2017-11-11
HUS2300025I1 (hu) 2023-08-28
RS58187B1 (sr) 2019-03-29
BR112015010102A2 (pt) 2017-07-11
NZ708859A (en) 2018-11-30
HUE059409T2 (hu) 2022-11-28
PE20150944A1 (es) 2015-06-20
TR201820824T4 (tr) 2019-01-21
HK1215255A1 (zh) 2016-08-19
SI3495358T1 (sl) 2022-06-30
SG11201503399XA (en) 2015-05-28
PL2922846T3 (pl) 2019-03-29
ZA201504052B (en) 2017-11-29
NO2023032I1 (en) 2023-08-25
US20170022192A1 (en) 2017-01-26
CA2890981C (en) 2022-07-05
ES2914793T3 (es) 2022-06-16
WO2014074661A1 (en) 2014-05-15
AU2018267545B2 (en) 2020-04-02
NL301238I2 (nl) 2023-10-04
AR094452A1 (es) 2015-08-05
MY194668A (en) 2022-12-12
AU2018267545A1 (en) 2018-12-13
JP2020002157A (ja) 2020-01-09
SG10201706897TA (en) 2017-09-28
US20220356180A1 (en) 2022-11-10
TW201422593A (zh) 2014-06-16
MA38072A1 (fr) 2016-07-29
USRE47929E1 (en) 2020-04-07
BR112015010102B1 (pt) 2022-02-08
EP3495358B1 (en) 2022-04-27
SG10201706985UA (en) 2017-10-30
AU2017201076B2 (en) 2018-11-15
MY175448A (en) 2020-06-29
EP3495358B8 (en) 2022-06-08
EP4071144A1 (en) 2022-10-12
UY35126A (es) 2014-05-30
KR102195194B1 (ko) 2020-12-24
EP2922846A1 (en) 2015-09-30
CL2015001231A1 (es) 2015-08-28
DK2922846T3 (en) 2019-01-21
AU2020203967A1 (en) 2020-07-16
EP3495358A1 (en) 2019-06-12
US10526321B2 (en) 2020-01-07
EP2922846B1 (en) 2018-10-03
AU2020203967B2 (en) 2020-10-22
MX2015005731A (es) 2015-09-16
IL238610A0 (en) 2015-06-30
CN104884454B (zh) 2017-11-28
ES2702148T3 (es) 2019-02-27
AU2013341186B2 (en) 2017-03-30
FIC20230028I1 (fi) 2023-08-28
KR20150081339A (ko) 2015-07-13
DK3495358T3 (da) 2022-05-23
CY1121188T1 (el) 2020-05-29
US10000480B2 (en) 2018-06-19
US20180265504A1 (en) 2018-09-20
CA2890981A1 (en) 2014-05-15
PH12015501004A1 (en) 2015-07-27
US20200071315A1 (en) 2020-03-05
HRP20181937T1 (hr) 2019-01-25
US9505748B2 (en) 2016-11-29
LT2922846T (lt) 2018-12-10
LTPA2023523I1 (hr) 2023-09-11
PL3495358T3 (pl) 2022-06-27
US11021475B2 (en) 2021-06-01
SI2922846T1 (sl) 2019-04-30
HUE041750T2 (hu) 2019-05-28
CY2023017I2 (el) 2024-02-16
JP6585231B2 (ja) 2019-10-02
CY2023017I1 (el) 2023-11-15
CN104884454A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
FR23C1030I1 (fr) Composes heterocycliques substitues par amide, utiles comme modulateurs d'il-12, il-23 et/ou de ifn-alpha
IL238554A0 (en) Alkyl-amide substituted pyridyl compounds are useful as modulators of il12, il23, and/or ifnα responses
EP2970508A4 (en) GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE
AP2013006984A0 (en) BicycloÄ3.2.1Üoctyl amide derivatives and uses of same
FR2989600B1 (fr) Tete de distribution et d'application.
EP2966422A4 (en) Method for determining an individual's weight and insole for the implementation thereof
EP3052190A4 (en) Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
HK1198921A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof dgla15-ohepa / 15-hetre
FR2974576B1 (fr) Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
SG11201503395TA (en) ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
MA43361A (fr) Composition pour le soin et la protection de cultures
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
HK1183891A1 (en) Copolymers containing phosphorylcholine groups and methods of preparing and using the same
EP3020762A4 (en) Vibration damping material and polymer composition
EP2900783A4 (en) DEHYDRATED GEL COMPOSITIONS AND USE METHOD THEREFOR
FR3002414B1 (fr) Composition rodenticide sous forme de cereales et/ou de graines agglomerees.
BR112015006272A2 (pt) ''uso cosmético, composto, composição cosmética e método de tratamento cosmético''
EP2893020A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE EXPRESSION AND SIGNALING OF PROTEINS ON CELL SURFACES
IL230655A0 (en) Derivatives n-hetero-converted in the amide ring, preparations containing them and their uses
BR112015000121A2 (pt) óleo essencial, composição cosmética ou farmacêutica, método de tratamento cosmético e uso cosmético de um óleo essencial
IL237432B (en) Amine salt, its crystals and pharmaceutical preparations containing it
WO2014092683A3 (en) Use of adipose septa protein modulators and compositions thereof
FR2988793B1 (fr) Missile tactique et masselotte d'equilibrage pour ce missile
TH165752B (th) สูตรผสมของเอนซาลูตแอมีด
ITFI20100031U1 (it) Pantaloni con vestibilita' regolabile